BioCentury
ARTICLE | Finance

2Q Stock Wrap-Up: Stand and deliver

Partnering, financing, Phase III data provided big bumps to biotechs in 2Q11

July 4, 2011 7:00 AM UTC

Several market cap bands tracked by BioCentury did well last quarter, as investors rewarded late-stage data and transformative deals.

The NYSE Arca Biotechnology Index and the BioCentury 100 each gained 7% in 2Q, while the NASDAQ Biotechnology Index was up 6%. The best performance came from biotechs with market caps over $5 billion, which had an average gain of 5%...